Gilead Sciences Inc

• Gilead shares declined due to institutional profit-taking and technical consolidation after earnings. • Acquired research and development charges created headwinds for reported GAAP profitability. • Analysts maintain a buy rating with an average price target of $171.76.

• Gilead reported third-quarter 2026 earnings and revenue surpassing Wall Street consensus expectations. • Management raised full-year 2026 product sales guidance to $31.0 billion. • Quarterly HIV franchise sales expanded 18% year-over-year with record Biktarvy market share.

• Gilead shares rose ahead of third-quarter financial results driven by therapy expectations. • Strategic pipeline updates and long-acting agents enhanced medium-term investor confidence. • Analysts raised price targets while technical indicators suggested buying conditions.

• Gilead partnered with Vir Biotechnology to develop next-generation oncology therapies. • Strong HIV franchise performance and bullish analyst coverage drove momentum. • The stock closed higher despite intraday volatility and profit-taking.

• Gilead partnered with Vir Biotechnology for solid tumor T-cell engager therapies. • Bank of America raised Gilead price targets on strong HIV therapy outlook. • Gilead reported annual revenue of $29.44B and net profit of $8.51B.

• Gilead pulled back due to profit-taking following a sustained multi-month rally. • Strong second-quarter revenue was driven by flagship HIV and Trodelvy franchises. • Analysts maintain Buy ratings with an average price target of $157.79.